Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.46 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.45 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407260 | 0.91 | CCNE2 (0.49) | CCNE2CCNE1CDK2GSK3BPIK3CD | |
| SCHEMBL3409731 | 0.88 | CCNE2 (0.46) | CCNE2CCNE1CDK2GSK3BPIK3CD | |
| SCHEMBL3407079 | 0.86 | GSK3B (0.56) | CCNE2CCNE1CDK2GSK3BPIK3CD | |
| SCHEMBL3407270 | 0.83 | SMN1; SMN2 (0.47) | ALDH1A1SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL3411396 | 0.83 | PIK3CD (0.62) | CCNE2CCNE1CDK2GSK3BPIK3CD | |
| SCHEMBL3407112 | 0.81 | CCNE2 (0.46) | MAPK1CCNE2CCNE1CDK2GSK3B | |
| SCHEMBL3407109 | 0.80 | GSK3B (0.53) | CCNE2CCNE1CDK2GSK3BPIK3CD | |
| SCHEMBL3405978 | 0.76 | GAA (0.45) | ATMALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL3408346 | 0.76 | GSK3B (0.50) | CCNE2CCNE1CDK2GSK3BMEN1 | |
| SCHEMBL11992032 | 0.76 | GSK3B (0.50) | CCNE2CCNE1CDK2GSK3BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268834-B2 | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme | NOVARTIS AG (CH) | 2012-09-18 | — | — | US | claimed |
| EP-2257529-A2 | PYRIDINES AND PYRAZINES AS INHIBITORS OF PI3K | Novartis AG (CH) | 2010-12-08 | — | — | EP | claimed |
| WO-2009115517-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | claimed |
| US-20090239847-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-09-24 | — | — | US | claimed |
| US-8846687-B2 | Pyrazine compounds as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| US-8846687-B2 | Pyrazine compounds as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| US-8846687-B2 | Pyrazine compounds as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| EP-2597085-A1 | Organic compounds | Novartis AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| EP-2597085-A1 | Organic compounds | Novartis AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-8268834-B2 | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme | NOVARTIS AG (CH) | 2012-09-18 | — | — | US | disclosed |
| US-8268834-B2 | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme | NOVARTIS AG (CH) | 2012-09-18 | — | — | US | disclosed |
| US-8268834-B2 | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme | NOVARTIS AG (CH) | 2012-09-18 | — | — | US | disclosed |
| US-20120214800-A1 | Organic Compounds | NOVARTIS AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120214800-A1 | Organic Compounds | NOVARTIS AG (CH) | 2012-08-23 | — | — | US | disclosed |
| EP-2257529-A2 | PYRIDINES AND PYRAZINES AS INHIBITORS OF PI3K | Novartis AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009115517-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009115517-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239847-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-09-24 | — | — | US | disclosed |
| US-20090239847-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-09-24 | — | — | US | disclosed |
| US-20090239847-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239847-A1 | Organic compounds | AR, TRPA1, IL33 | MAPK1 2307/4885CCNE2 2451/4885CCNE1 2616/4885 |
| US-20120214800-A1 | Organic Compounds | AR, TRPA1, IL33 | MAPK1 2307/4885CCNE2 2451/4885CCNE1 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.